News

Keros Therapeutics: Interesting Early Data From A Promising Molecule (Downgrade) (KROS)

3 Mins read

In April, I covered Keros Therapeutics, Inc. (NASDAQ:KROS), and found it interesting. Keros had three published datasets from three clinical-stage programs. The stock had a short rally after my coverage, then went down, took another small leap, and then went down

Response summary

RP2D Patients

All evaluable patients

HTB evaluable patients

Overall Erythroid Response (HI-E or TI) n (%)

19/37 (51.4)

11/22 (50)

IWG 2006 HI-E, n (%)

19/37 (51.4)

11/22 (50)

TI ≥8 weeks, n (%)

11/26 (42.3)

9/22 (40.9)

RS+, n (%)

8/19 (42.1)

6/17 (35.3)

Non-RS, n (%)

3/7 (42.9)

3/5 (60)

Read the full article here

Related posts
News

Alphabet Q1 2025: Impressive Results For This Undervalued Gem (NASDAQ:GOOG)

1 Mins read
This article was written by Follow Hi there, welcome to my profile. My name is Eugenio Catone, I live in Italy and…
News

Flex (FLEX) Stock: Targeting High-Growth Data Center Business

1 Mins read
This article was written by Follow I am a freelancer with a business education who loves to discover new ideas for long…
News

Alerian MLP Is A Great Option For A Lazy Investor (Rating Upgrade) (NYSEARCA:AMLP)

1 Mins read
This article was written by Follow The Value Portfolio specializes in building retirement portfolios and utilizes a fact-based research strategy to identify…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *